GlaxoSmithKline is one of Europe's leading pharmaceutical developers but like its peers, it has been wrestling with the triple threats of generic competition, ever more rigorous regulatory scrutiny, and the challenge of keeping its drug development pipeline filled. GSK's problems were, arguably, more serious than some of its rivals, resulting in its demotion from the coveted position as global #2 several years ago. It now lags behind its Swiss rivals by overall revenues. Recently, the group has been tweaking its broadly diversified portfolio in order to specialise on a smaller number of key pharmaceutical segments, primarily respiratory and HIV drugs (the latter from specialist unit ViiV Healthcare) and vaccines. GSK had five blockbuster brands in 2018: HIV treatments Triumeq (sales of £2.7bn) and Tivicay (£1.6bn), respiratory drugs Seretide/Advair (£2.4bn) and the Ellipta family (£2.1bn) and shingles vaccine Shingrix. Respiratory drugs now account for more than a third of the group's pharmaceutical sales and HIV products for well over another quarter. Other significant pharma products, though now mostly in slow decline post-patent, include Lamictal, Augmentin and Avodart. Key vaccines include pediatric vaccine Infanrix/Pediarix and Bexsero against meningitis as well as vaccines against influenza and hepatitis. Greater specialisation has resulted in stronger financial performance. Group revenues hit a new high of £30.8bn in 2018, while net income soared to £4.1bn. Pharma sales were flat at £17.3bn, but vaccines rose strongly to £5.9bn. The group has also dramatically expanded its position in OTC with a series of major deals. GSK Consumer Healthcare is now the global #1 in its sector (see separate page), but is expected to be spun off as a separate company by 2022. Former OTC chief Emma Walmsley became group CEO in 2017, the first woman ever to lead a Big Pharma company.
Capsule checked 2nd April 2019
Which agencies handle advertising for GlaxoSmithKline? Find out more from the Account Assignments database
Who are the competitors of GlaxoSmithKline? See Pharmaceutical Sector
Advertising Expenditure? See ranking of declared spend
Key decisionmakers at GSK? Find out more from the Account Assignments database
Account assignments & selected contact information
Adbrands Account Assignments tracks account management for the world's leading brands and companies, including details of which advertising agency handles which accounts in which countries for major markets.
Historical profile information for GlaxoSmithKline
Recent stories from Adbrands Update:
Adbrands Daily Update 5th Dec 2018: Hot on the heels of its deal to sell its nutritional drinks portfolio to Unilever, GSK signed off on the purchase of US drug developer Tesaro for $5.1bn. That company's portfolio includes Zejula, a new type of cancer drug known as a PARP inhibitor, competing with AstraZeneca's Lynparza. It marks GSK's return to the oncology market after it sold its previous collection of drugs to Novartis four years ago.
Adbrands Weekly Update 11th Oct 2018: Not the best of weeks for WPP. Four big reviews ended in partial or total losses for the group. First up was GlaxoSmithKline's global media. GroupM handled most of the account worldwide, split between Mediacom, Mindshare and Essence. Omnicom's PHD had the US, Australia and New Zealand. However, the pharma group has chosen Publicis to carry forward the account, in a newly created dedicated unit, PlatformGSK.
Adbrands Weekly Update 24th May 2018: Trade source Fierce Pharma has compiled an interesting table of the top drugs sold in the US over the past 25 years, using cumulative sales figures. It passed its peak several years ago now, but Pfizer's cholesterol drug Lipitor is still the clear leader with total sales to-date of almost $95bn. It could soon be toppled, though, by AbbVie's Humira, a treatment for auto-immune conditions. Sales are already almost $76bn, and Humira is expected to become the first drug ever to top $20bn in sales in a single year before its patent expires in 2023. In third place for now is Nexium, from AstraZeneca, for acid reflux and ulcers. It too is past its peak, but cumulative sales currently stand at over $72bn. GSK's Advair and Amgen's Enbrel rounded out the top five at $69bn and $68bn respectively. (See full feature here).
Adbrands Weekly Update 10th May 2018: Another week, another big media review. GlaxoSmithKline is the latest global giant to reconsider media buying and planning arrangements. It piles yet more pressure onto WPP, whose Mediacom has most of the global business except the US, where Omnicom's PHD is the incumbent. Worldwide billings are around $1.7bn. The pitch is wide open, with all six major marketing groups invited to compete for the business.
All rights reserved © Mind Advertising Ltd 1998-2019